Sheng Hu

机构：Anhui Agricultural University · ORCID：0000-0002-5565-7072

发表论文 89 篇 · 总被引 840 次 · h-index 17

代表论文

• First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial (2025 · Nature Medicine · 被引 20)
• Resistance to immunotherapy in non-small cell lung cancer: Unraveling causes, developing effective strategies, and exploring potential breakthroughs (2025 · Drug Resistance Updates · 被引 16)
• Efficacy and safety of IBI351 (fulzerasib) monotherapy in KRASG12C inhibitor-naïve Chinese patients with KRASG12C-mutated metastatic colorectal cancer: a pooled analysis from phase I part of two studies (2025 · Signal Transduction and Targeted Therapy · 被引 14)
• Higher prognostic nutritional index is associated with lower incidence of sarcopenia (2025 · Geriatric Nursing · 被引 7)
• Sacituzumab tirumotecan (sac-TMT) in combination with tagitanlimab (anti-PD-L1) in first-line (1L) advanced non-small-cell lung cancer (NSCLC): Non-squamous cohort from the phase II OptiTROP-Lung01 study. (2025 · Journal of Clinical Oncology · 被引 6)
• Smooth muscle contractility of laser-enucleated prostate tissues and impacts of preoperative α1-blocker treatment in patients with and without catheterization (2025 · Scientific Reports · 被引 5)